Thanks to know-how and inventor’s team, Occlugel has developed new degradable drug delivery system (DDDS) for loco-regional treatments. Local delivery of antibiotics, glaucoma treatment or pain killer is tunable from few days to few weeks. Occlugel's DDDS are easy to inject per or post-operatively and could offer safety for physicians, a benefit for patients in accordance with the requirements of health insurance. These innovative and disruptive DDDS allow a swift access to market with a high potential for differentiation.
Over the years Occlugel has created and developed the first degradable microspheres for embolization and chemoembolization in the world and had transferred it successfully to an US industrial. Recently, an original technology of microspheres with X-rays and MRI visibility was transferred by Occlugel to a European pharmaceutical group. Occlugel owns a genuine expertise in process transferring of its technologies towards industry and is looking for long-standing relationships to develop its new DDDS.
Company Details
- Employees
- 5
- Address
- 17 Bis Avenue Des Andes, Les Ulis,île-De-France 91940,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- occlugel.com
- HQ
- les Ulis, Île-de-France
Occlugel Sas. Questions
Occlugel Sas.'s website is occlugel.com
Occlugel Sas.'s LinkedIn profile is https://fr.linkedin.com/company/occlugel-sas
Occlugel Sas. has
5 employees.
View email and phone details for 5
employees at Occlugel Sas..
Occlugel Sas.'s industry is
Biotechnology Research
Occlugel Sas.'s top competitors are
Encefa,
Hephaistos-Pharma,
Jalon Therapeutics,
Exhalon,
Shimadzu Diagnostics Europe,
Infocus Therapeutics,
Karcinolys,
Ennodc,
Orakl Oncology,
Medincell.
Occlugel Sas.'s categories are Biotechnology Research
